For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Ngm Biopharmaceuticals, Inc.

USPTO Granted Patents = 73

CIPO Patents = 2

EPO Patents = 13

Trademarks = 2

Forward Citations = 697

Loading Chart...

Loading Chart...

43 inventors (with patents filed for the assignee):

Lei Ling (27 out of 29 patents)

Darrin Anthony Lindhout (27 out of 27 patents)

Hugo Matern (21 out of 21 patents)

4. Wenyan Shen (16 out of 47 patents)

5. Yan Wang (14 out of 14 patents)

6. Jian Luo (13 out of 32 patents)

7. Raj Haldankar (11 out of 11 patents)

8. Hui Tian (10 out of 18 patents)

9. Zhonghao Liu (10 out of 10 patents)

10. Betty Chan Li (10 out of 10 patents)

11. Kalyani Mondal (9 out of 9 patents)

12. Daniel David Kaplan (8 out of 8 patents)

13. Yu Chen (7 out of 12 patents)

14. Taruna Arora (7 out of 24 patents)

15. Jie Tang (5 out of 10 patents)

Core Competencies:

ILT-Binding Agents

Polynucleotides

Beta Klotho Antibodies

Combination Therapy

C3-Binding Agents

FGF19 Polypeptides

ANGPTL8-Binding Agents

Bile Acid Homeostasis

Metabolic Disorders

Glucagon Receptor Antibodies

LEAP2 Binding Agents

Wasting Syndrome Treatments

73 patents: Sort by Forward Citations

1. 12410251 - ILT-binding agents and methods of use thereof (2025-09-09),

2. 12378312 - Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof (2025-08-05),

3. 12240899 - LAIR-1-binding agents and methods of use thereof (2025-03-04),

4. 12187796 - ILT3-binding agents and methods of use thereof (2025-01-07),

5. 12180289 - Binding proteins and methods of use thereof (2024-12-31),

6. 12173060 - Compositions and methods of use for treating metabolic disorders (2024-12-24),

7. 11845802 - Combination therapy with a glucagon receptor (GCGR) antibody and an anti-CD3 antibody (2023-12-19),

8. 11802155 - ILT-binding agents and methods of use thereof (2023-10-31),

9. 11767359 - C3-binding agents and methods of use thereof (2023-09-26),

10. 11760802 - ILT3-binding agents and methods of use thereof (2023-09-19),

11. 11732049 - Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor (2023-08-22),

12. 11667708 - Anti-human beta klotho antibody or binding fragment thereof and methods of their use (2023-06-06),

13. 11596676 - Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof (2023-03-07),

14. 11566067 - Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof (2023-01-31),

15. 11564972 - Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject (2023-01-31),

NGM Biopharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing transformative medicines for patients with life-threatening diseases. They aim to improve the lives of patients by targeting the underlying mechanisms of disease to develop effective and innovative therapies. With a dedicated team of scientists and researchers, NGM is committed to bringing novel therapeutic options to the healthcare market.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

73 Patents

#17 in South San Francisco, CA

#1,156 in California

#4,849 in US

#9,949 in the World

South San Francisco, CA, United States of America

Ngm Biopharmaceuticals, Inc.

Forward Citations = 697

43 inventors:

Lei Ling (27 out of 29 patents)

Darrin Anthony Lindhout (27 out of 27 patents)

Hugo Matern (21 out of 21 patents)

4. Wenyan Shen (16 out of 47 patents)

5. Yan Wang (14 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…